LYNK Pharmaceuticals
Pioneering novel treatments for oncology, immunology, and inflammatory diseases since 2018.
Pioneering novel treatments for oncology, immunology, and inflammatory diseases since 2018.
LYNK Pharmaceuticals is a biotech startup founded in 2018 and is dedicated to pioneering novel treatments for oncology, immunology, and inflammatory diseases. Based in Hangzhou, Zhejiang, China, the company has garnered significant attention in the biotechnology, health care, and pharmaceutical industries. LYNK Pharmaceuticals recently secured a noteworthy CNY122.00M Series C investment on 21 September 2023. The investment came from a group of prominent investors including Lilly Asia Ventures, New Alliance Capital, 杭州海邦投资管理有限公司, Prosperity Investment, Zhongjin Shengshi Investment, Lianxing Capital, Howbuy Primary Fund, and Haomai Fund of Funds.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | CNY122.00M | 8 |
|
21 Sep 2023 |
| Series C | CNY200.00M | 4 |
|
31 May 2023 |
| Series B | $50.00M | 5 |
|
27 Aug 2021 |
| Series A | $20.00M | 1 |
|
15 Nov 2020 |
| Series A | Unknown | 4 |
|
19 Apr 2020 |
No recent news or press coverage available for LYNK Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
